The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune-Related Adverse Events

Alexandra Ladouceur,Aiarpi Ezdoglian,Jeffrey A. Sparks,Marie Hudson,Shahin Jamal,Alison Clifford,Janet Roberts,Carrie Ye

DOI: https://doi.org/10.1016/j.rdc.2024.01.003

IF: 2.032

2024-02-24

Rheumatic Disease Clinics of North America

Abstract:• Immune checkpoint inhibitor (ICI)-associated inflammatory arthritis has lower rates of seropositivity for rheumatoid factor and antibodies to citrullinated peptides than rheumatoid arthritis. • Most of the ICI-associated myositis has elevated creatine kinase, and myositis-specific antibodies are positive in up to one-quarter of patients. Although there are false positives, the presence of TIF1γ or NXP2 can help identify paraneoplastic myositis. • Similar to polymyalgia rheumatica, most of the Immune checkpoint inhibitor (ICI)-associated inflammatory arthritis has lower rates of seropositivity for rheumatoid factor and antibodies to citrullinated peptides than rheumatoid arthritis. Most of the ICI-associated myositis has elevated creatine kinase, and myositis-specific antibodies are positive in up to one-quarter of patients. Although there are false positives, the presence of TIF1γ or NXP2 can help identify paraneoplastic myositis. Similar to polymyalgia rheumatica, most of the

rheumatology